# NCT02579811 (NCT02579811)

> Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02579811
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Case Comprehensive Cancer Center
- Conditions: Metastatic Renal Cell Cancer
- Interventions: Axitinib
- Enrollment: 40
- Primary outcome: Median Progression-free Survival

## Indexed commentary on NCT02579811 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02579811
